Mu opioid receptor knockdown in the substantia nigra/ventral tegmental area by synthetic small interfering RNA blocks the rewarding and locomotor effects of heroin

Neuroscience

Volumn 158, Issue 2, 2009, Pages 474-483

  Zhang, Y ^a   Landthaler, M ^a   Schlussman, S D ^a   Yuferov, V ^a   Ho, A ^a   Tuschl, T ^a   Kreek, M J ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

conditioned place preference; heroin; locomotor activity; MOP r; mouse; siRNAs

Indexed keywords

DIAMORPHINE; MESSENGER RNA; MU OPIATE RECEPTOR; SMALL INTERFERING RNA;

ARTICLE; BEHAVIOR; CONTROLLED STUDY; DRUG ABUSE; DRUG ACTIVITY; DRUG MECHANISM; DRUG TARGETING; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLACE PREFERENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM;

ANALYSIS OF VARIANCE; ANIMALS; AUTORADIOGRAPHY; HEROIN; HEROIN DEPENDENCE; LOCOMOTION; MALE; MICE; MICE, INBRED C57BL; REACTION TIME; RECEPTORS, OPIOID, MU; REWARD; RNA, SMALL INTERFERING; SUBSTANTIA NIGRA; TIME FACTORS; VENTRAL TEGMENTAL AREA;

EID: 58149471555     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2008.09.039     Document Type: Article

References (43)

1. Aghajanian G.K. Tolerance of locus coeruleus neurones to morphine and suppression of withdrawal response by clonidine. Nature 276 (1978) 186-188
2. Bals-Kubik R., Ableitner A., Herz A., and Shippenberg T.S. Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats. J Pharmacol Exp Ther 264 (1993) 489-495
3. Baumeister A.A., Hurry M., Curtis W., Chaney T.M., Wolf E., and Leoni R.R. The antinociceptive and motivational effects of intranigral injection of opioid agonists. Neuropharmacology 32 (1993) 1299-1303
4. Becker A., Grecksch G., Brodemann R., Kraus J., Peters B., Schroeder H., Thiemann W., Loh H.H., and Hollt V. Morphine self-administration in mu-opioid receptor-deficient mice. Naunyn Schmiedebergs Arch Pharmacol 361 (2000) 584-589
5. Becker A., Grecksch G., Kraus J., Loh H.H., Schroeder H., and Hollt V. Rewarding effects of ethanol and cocaine in mu opioid receptor-deficient mice. Naunyn Schmiedebergs Arch Pharmacol 365 (2002) 296-302
6. Boehnke S.E., and Rasmusson D.D. Time course and effective spread of lidocaine and tetrodotoxin delivered via microdialysis: an electrophysiological study in cerebral cortex. J Neurosci Methods 105 (2001) 133-141
7. Contarino A., Picetti R., Matthes H.W., Koob G.F., Kieffer B.L., and Gold L.H. Lack of reward and locomotor stimulation induced by heroin in mu-opioid receptor-deficient mice. Eur J Pharmacol 446 (2002) 103-109
8. David V., Durkin T.P., and Cazala P. Differential effects of the dopamine D2/D3 receptor antagonist sulpiride on self-administration of morphine into the ventral tegmental area or the nucleus accumbens. Psychopharmacology 160 (2002) 307-317
9. David V., Matifas A., Gavello-Baudy S., Decorte L., Keiffer B.L., and Cazala P. Brain regional fos expression elicited by the activation of mu- but not delta-opioid receptors of the ventral tegmental area: evidence for an implication of the ventral thalamus in opiate reward. Neuropsychopharmacology 33 (2008) 1746-1759
10. Devine D.P., and Wise R.A. Self-administration of morphine, DAMGO, and DPDPE into the ventral tegmental area of rats. J Neurosci 14 (1994) 1978-1984
11. Di Chiara G., and Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 85 (1988) 5274-5278
12. Di Chiara G., and North R.A. Neurobiology of opiate abuse. Trends Pharmacol Sci 13 (1992) 185-193
13. Dorn G., Patel S., Wotherspoon G., Hemmings-Mieszczak M., Barclay J., Natt F.J., Martin P., Bevan S., Fox A., Ganju P., Wishart W., and Hall J. siRNA relieves chronic neuropathic pain. Nucleic Acids Res 32 (2004) e49
14. Farah M.H. RNAi silencing in mouse models of neurodegenerative diseases. Curr Drug Deliv 4 (2007) 161-167
15. Franklin K.B.J., and Paxinos G. The mouse brain in stereotaxic coordinates (1997), Academic Press, Inc, New York
16. Grimm D., and Kay M.A. Therapeutic short hairpin RNA expression in the liver: viral targets and vectors. Gene Ther 13 (2006) 563-575
17. Hoyer D., Thakker D.R., Natt F., Maier R., Huesken D., Muller M., Flor P., van der Putten H., Schmutz M., Bilbe G., and Cryan J.F. Global down-regulation of gene expression in the brain using RNA interference, with emphasis on monoamine transporters and GPCRs: implications for target characterization in psychiatric and neurological disorders. J Recept Signal Transduct Res 26 (2006) 527-547
18. Institue of Laboratory Animal Resources on Life Sciences, National Research Council. Guide for the care and use of laboratory animals (1996), National Academy of Sciences, Washington, DC
19. Johnson R.E., and McCagh J.C. Buprenorphine and naloxone for heroin dependence. Curr Psychiatry Rep 2 (2000) 519-526
20. Johnson S.W., and North R.A. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci 12 (1992) 483-488
21. Johnson S.W., and North R.A. Two types of neurone in the rat ventral tegmental area and their synaptic inputs. J Physiol 450 (1992) 455-468
22. Kieffer B.L. Opioids: first lessons from knockout mice. Trends Pharmacol Sci 20 (1999) 19-26
23. Kieffer B.L., and Gaveriaux-Ruff C. Exploring the opioid system by gene knockout. Prog Neurobiol 66 (2002) 285-306
24. Margolis E.B., Hjelmstad G.O., Bonci A., and Fields H.L. Kappa-opioid agonists directly inhibit midbrain dopaminergic neurons. J Neurosci 23 (2003) 9981-9986
25. Mathieu-Kia A.M., and Besson M.J. Repeated administration of cocaine, nicotine and ethanol: effects on preprodynorphin, preprotachykinin A and preproenkephalin mRNA expression in the dorsal and the ventral striatum of the rat. Brain Res Mol Brain Res 54 (1998) 141-151
26. Matthes H.W., Maldonado R., Simonin F., Valverde O., Slowe S., Kitchen I., Befort K., Dierich A., Le Meur M., Dolle P., Tzavara E., Hanoune J., Roques B.P., and Kieffer B.L. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 383 (1996) 819-823
27. Matthews R.T., and German D.C. Electrophysiological evidence for excitation of rat ventral tegmental area dopamine neurons by morphine. Neuroscience 11 (1984) 617-625
28. Minami M., Onogi T., Toya T., Katao Y., Hosoi Y., Maekawa K., Katsumata S., Yabuuchi K., and Satoh M. Molecular cloning and in situ hybridization histochemistry for rat mu-opioid receptor. Neurosci Res 18 (1994) 315-322
29. Nestler E.J. Molecular mechanisms of drug addiction. J Neurosci 12 (1992) 2439-2450
30. Pasternak G.W. Pharmacological mechanisms of opioid analgesics. Clin Neuropharmacol 16 (1993) 1-18
31. Pierce R.C., and Kumaresan V. The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse?. Neurosci Biobehav Rev 30 (2006) 215-238
32. Reynolds A., Leake D., Boese Q., Scaringe S., Marshall W.S., and Khvorova A. Rational siRNA design for RNA interference. Nat Biotechnol 22 (2004) 326-330
33. Roberts A.J., McDonald J.S., Heyser C.J., Kieffer B.L., Matthes H.W., Koob G.F., and Gold L.H. Mu-opioid receptor knockout mice do not self-administer alcohol. J Pharmacol Exp Ther 293 (2000) 1002-1008
34. Snove Jr. O., Nedland M., Fjeldstad S.H., Humberset H., Birkeland O.R., Grunfeld T., and Saetrom P. Designing effective siRNAs with off-target control. Biochem Biophys Res Commun 325 (2004) 769-773
35. Sora I., Elmer G., Funada M., Pieper J., Li X.F., Hall F.S., and Uhl G.R. Mu opiate receptor gene dose effects on different morphine actions: evidence for differential in vivo mu receptor reserve. Neuropsychopharmacology 25 (2001) 41-54
36. Sora I., Takahashi N., Funada M., Ujike H., Revay R.S., Donovan D.M., Miner L.L., and Uhl G.R. Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc Natl Acad Sci U S A 94 (1997) 1544-1549
37. Surratt C.K., Johnson P.S., Moriwaki A., Seidleck B.K., Blaschak C.J., Wang J.B., and Uhl G.R. -Mu opiate receptor. Charged transmembrane domain amino acids are critical for agonist recognition and intrinsic activity. J Biol Chem 269 (1994) 20548-20553
38. Thakker D.R., Natt F., Husken D., Maier R., Muller M., van der Putten H., Hoyer D., and Cryan J.F. Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference. Proc Natl Acad Sci U S A 101 (2004) 17270-17275
39. Thakker D.R., Natt F., Husken D., van der Putten H., Maier R., Hoyer D., and Cryan J.F. siRNA-mediated knockdown of the serotonin transporter in the adult mouse brain. Mol Psychiatry 10 (2005) 782-789 714
40. Thompson R.C., Mansour A., Akil H., and Watson S.J. Cloning and pharmacological characterization of a rat mu opioid receptor. Neuron 11 (1993) 903-913
41. Unterwald E.M., Tempel A., Koob G.F., and Zukin R.S. Characterization of opioid receptors in rat nucleus accumbens following mesolimbic dopaminergic lesions. Brain Res 505 (1989) 111-118
42. Wise R.A. Addictive drugs and brain stimulation reward. Annu Rev Neurosci 19 (1996) 319-340
43. Zhang Y., Butelman E.R., Schlussman S.D., Ho A., and Kreek M.J. Effect of the kappa opioid agonist R-84760 on cocaine-induced increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice. Psychopharmacology 173 (2004) 146-152